State Street SPDR S&P Pharmaceuticals ETF
XPH
80 hedge funds and large institutions have $185M invested in State Street SPDR S&P Pharmaceuticals ETF in 2019 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 18 increasing their positions, 21 reducing their positions, and 16 closing their positions.
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
31% more capital invested
Capital invested by funds: $141M → $185M (+$43.3M)
18.32% more ownership
Funds ownership: 56.35% → 74.66% (+18%)
8% more funds holding
Funds holding: 74 → 80 (+6)
14% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$52.5M |
| 2 |
Barclays
London,
United Kingdom
|
+$6.1M |
| 3 |
CI
Cavalier Investments
Alpharetta,
Georgia
|
+$2.25M |
| 4 |
Envestnet Asset Management
Chicago,
Illinois
|
+$1.46M |
| 5 |
Jane Street
New York
|
+$1.29M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
-$7.62M |
| 2 |
JP Morgan Chase
New York
|
-$5.61M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$5.5M |
| 4 |
Morgan Stanley
New York
|
-$5.13M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$3.88M |
XPH Hedge Fund Activity: Q1 2019 in Review
80 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q1 2019, worth a combined $185M — up 31% from $141M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new XPH positions and 16 closed out — a net gain of 6 holders — while 18 added to existing stakes and 21 trimmed.
The largest buyer was Credit Suisse, opening a new position worth an estimated $52.5M. The largest seller was BNP Paribas Financial Markets, exiting entirely with an estimated $7.62M sold.
- 80 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q1 2019, up from 74 in Q4 2018.
- Funds reported $185M of State Street SPDR S&P Pharmaceuticals ETF stock for Q1 2019, up 31% quarter-over-quarter.
- 22 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q1 2019 and 16 closed out, a net change of +6 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q1 2019 was Credit Suisse, an estimated $52.5M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q1 2019 was BNP Paribas Financial Markets, an estimated $7.62M sold.
Based on aggregated 13F filings for Q1 2019.